Ignota Labs

London, United Kingdom Founded: 2021 • Age: 5 yrs
AI-driven toxicity prediction tools for early-stage drug discovery scientists
Annual revenue - Latest available
Total funding $6.9M 1 rounds
Employees 6 Tracked headcount
Investors 5 Known backers
Products 1 Services tracked
Competitors 10 Brand Intelligence

About Ignota Labs

Ignota Labs is a company based in London (United Kingdom) founded in 2021 by Layla Hosseini-Gerami and Sam Windsor. Ignota Labs has raised $6.9 million across 1 funding round from investors including Montage Ventures, AIX Ventures and Modi Ventures. The company has 6 employees as of October 31, 2024. Ignota Labs offers products and services including SAFEPATH. Ignota Labs operates in a competitive market with competitors including Fagron, RareStone Group, Syntis, Pharmedium and Revelation Pharma, among others.

  • Headquarter London, United Kingdom
  • Employees 6 as on 31 Oct, 2024
  • Founders Layla Hosseini-Gerami, Sam Windsor
  • Sectors
    Healthcare
  • Email
    Locked
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
  • Legal Name Absoluteai Ltd
  • Date of Incorporation 14 Oct, 2021
  • Jurisdiction LONDON, ENGLAND
Operational Areas
Healthcare → Healthcare Services & Infrastructure Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Total Equity Funding
    $6.9 M (USD)

    in 1 rounds

  • Latest Funding Round
    $6.9 M (USD), Seed

    Feb 26, 2025

  • Investors
  • Employee Count
    6

    as on Oct 31, 2024

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Ignota Labs

Ignota Labs offers a comprehensive portfolio of products and services, including SAFEPATH.

Product name locked
Category locked
Primary

AI model identifies and mitigates drug safety issues in trials.

Funding Insights of Ignota Labs

Ignota Labs has successfully raised a total of $6.9M through 1 strategic funding round. The most recent funding activity was a Seed round of $6.9 million completed in February 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

Investors in Ignota Labs

Ignota Labs has secured backing from 5 investors, including venture fund investors. Prominent investors backing the company include Montage Ventures, AIX Ventures and Modi Ventures.

All
Venture Fund
Investor Description Founded Year Domain Location
US focused growth stage VC firm
Locked Locked Locked
Venture capital is provided to AI-powered companies by AIX Ventures.
Locked Locked Locked
Modi Ventures is focused on investments in tech-bio convergence.
Locked Locked Locked
Premium access

Investor details for Ignota Labs

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Ignota Labs

Investments
Premium access

Investment portfolio details for Ignota Labs

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - Ignota Labs

Premium access

Detailed financials for Ignota Labs

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Ignota Labs Comparisons

Ignota Labs Primary company
Description
AI-driven toxicity prediction tools for early-stage drug dis...
Location
London, United Kingdom
Founded Year
2021
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
6
As of 2024
Premium access

Peer comparison for Ignota Labs

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Ignota Labs

Ignota Labs operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Fagron, RareStone Group, Syntis, Pharmedium and Revelation Pharma, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Drug compounding services are provided by Fagron.
Locked Locked Locked
Provider of network and treatments to individuals and their families affected by rare diseases drugs
Locked Locked Locked
Drug compounding services are provided by Syntis in healthcare.
Locked Locked Locked
Drug compounding services are provided to healthcare facilities nationwide.
Locked Locked Locked
A network of compounding pharmacies is operated nationwide.
Premium access

Detailed competitors of Ignota Labs

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Ignota Labs

Premium access

Complete news archive for Ignota Labs

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Ignota Labs

Ignota Labs was founded in 2021 and raised its 1st funding round 4 years after it was founded.

Ignota Labs is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.

Sam Windsor is the current CEO of Ignota Labs. They have also founded this company.

Ignota Labs is a funded company, having raised a total of $6.9M across 1 funding round to date.

As of Oct 31, 2024, the latest employee count at Ignota Labs is 6.

Ignota Labs is a technology startup in the pharmaceutical sector that provides AI-driven toxicity prediction tools for early-stage drug discovery scientists. Their suite of tools, TOXSCAPE, helps scientists identify and understand safety issues during the drug discovery process, reducing expensive setbacks and delays.

Ignota Labs's top competitors include Syntis, Fagron and Medac.

Ignota Labs offers SAFEPATH.

Ignota Labs has 5 investors. Key investors include Montage Ventures, AIX Ventures, Modi Ventures, Blue Wire Capital, and Gaingels.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available